source
- Orphan drug sales projected to exceed 21% of prescription market by 2032, driven by strong pipeline and policy supportOrphan drug developers continue to see robust sales growth even as the broader pharmaceutical industry faces pricing and policy turbulence. The latest Evaluate Orphan Drugs Report highlights that s…
- Oculis’ investigational eye drop OCS-01 fails Phase 3 trials for diabetic macular edema, shares tumbleOculis announced that its experimental eye drop OCS-01 did not meet primary endpoints in two Phase 3 studies aimed at treating diabetic macular edema. The trials were intended to evaluate the drug…